Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9752W HIGH $13.42
Volume
50.19 K
Value Traded
66.48 K
Short % Float
1.18%
Days to Cover
1.0
-19.25%Week
-5.11%1 Month
-12.16%3 Month
+17.12%6 Month
-99.95%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
8.56 M
EPS (TTM)
-2.38
P/E Ratio
-
Ent. Value
-213.47 K
Total Shares
6.59 M
Float Shares
4.74 M
Insiders
28.08%
Institutions
4.39%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
MTVA Catalyst Timeline
Dated clinical, regulatory and corporate events for MetaVia Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for MetaVia Inc.
402Total events
11Upcoming
118Tier-1 (high impact)
2016 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Quarterly UpdateCorporate
MetaVia reports third quarter 2026 financial results and corporate update
▲Interim AnalysisDA-1726Trial
Additional positive interim data from Phase 1 Part 3B of DA-1726 in obesity
obesitysource ↗
▲Interim Efficacy DataDA-1726Clinical Data
DA-1726 Phase 1 Part 3B interim data: 68% placebo-adjusted liver fat reduction, 13.5% weight loss
obesitysource ↗
●Safety Data UpdateDA-1726Clinical Data
No new GI AEs after Week 9 through Day 109; one SAE of severe vomiting
obesitysource ↗
▲Oral PresentationDA-1726Presentation
DA-1726 Phase 1 Part 3B data presented orally at Precision Liver Symposium
obesitysource ↗
▲Interim Efficacy DataDA-1726Clinical Data
DA-1726 Phase 1 Part 3B interim data: 68.1% placebo-adjusted liver fat reduction, 13.5% weight loss at Day 109
MetALD and ALDsource ↗
▲Additional DataDA-1726Clinical Data
Additional Phase 1 Part 3B interim data: 1.47 mg/dL placebo-adjusted uric acid reduction at 16 weeks (p<0.001)
MetALD and ALDsource ↗
▲Oral PresentationDA-1726Presentation
Oral presentation of DA-1726 Phase 1 Part 3B interim data at Precision Liver Symposium
MetALD and ALDsource ↗
▲Preclinical PoCDA-1726Preclinical
Preclinical tissue distribution study shows highest DA-1726 exposure in adipose tissue and prolonged retention
obesitysource ↗
▲Preclinical PoCDA-1726Preclinical
Preclinical tissue distribution findings for DA-1726 showing highest adipose exposure and prolonged retention
▲Enrollment MilestoneDA-1726Trial
All active patients in both cohorts completed dose titration to highest target doses (48 mg and 64 mg)
obesitysource ↗
▲Enrollment CompleteDA-1726Trial
All active patients completed dose titration in Part 3 cohorts
obesitysource ↗
▲Enrollment CompleteDA-1726Trial
Completed dose titration in Phase 1 Part 3 study of DA-1726
obesitysource ↗
▲Dose Finding UpdateDA-1726Trial
Completion of dose titration in 16-week Phase 1 Part 3 study; all active patients reached 48 mg and 64 mg
MetALD and ALDsource ↗
◆Oral PresentationPresentation
MetaVia CEO to participate in fireside chat at Life Sciences Virtual Investor Forum
◆Late-BreakerDA-1726Presentation
Late-breaking abstract accepted for poster presentation at ADA 2026
obesitysource ↗
◆Late-BreakerDA-1241Presentation
Late-breaking abstract accepted for poster presentation at ADA 2026 (vanoglipel + metformin combo)
Type 2 diabetessource ↗
▲Oral PresentationDA-1726Presentation
Late-breaking poster presentation of DA-1726 Phase 1 higher-dose cohort results at ADA 2026
obesitysource ↗
▲Oral PresentationDA-1241Presentation
Late-breaking preclinical study of vanoglipel + metformin in T2D mouse model at ADA 2026
type 2 diabetessource ↗
▲Oral PresentationDA-1241Presentation
Presented preclinical combination data for vanoglipel at ADA 2026
MASH and type 2 diabetessource ↗
◆Late-BreakerDA-1726Presentation
Late-breaking abstract accepted for poster presentation at EASL Congress 2026
obesitysource ↗
◆Oral PresentationDA-1726Presentation
Late-breaking poster presentation of Phase 1 data for DA-1726 at EASL Congress 2026
obesity and MASHsource ↗
▲Topline ReadoutDA-1726Clinical Data
Phase 1 MAD 48 mg cohort topline results: up to 9.1% mean body weight reduction at Day 54
obesitysource ↗
◆Enrollment UpdateDA-1726Trial
Ongoing Phase 1 Part 3a/3b titration studies continue to evaluate extended treatment at higher-dose levels
obesitysource ↗
▲PublicationDA-1241Presentation
Peer-reviewed publication supporting anti-fibrotic potential of vanoglipel in MASH
MASHsource ↗
▲First Patient DosedDA-1726Trial
First patient dosed in Phase 1 Part 3 16-week titration study of DA-1726
obesitysource ↗
▲Oral PresentationDA-1726Presentation
Presented additional data at EASL Congress 2026
obesity and MASHsource ↗
▲PublicationDA-1241Presentation
Published peer-reviewed preclinical research on vanoglipel
MASHsource ↗
▲First Patient DosedDA-1726Trial
First patient dosed in Part 3 of Phase 1 trial of DA-1726
obesitysource ↗
◆Trial InitiationDA-1726Trial
Initiation of Phase 1 Part 3 16-week titration study (48 mg 1-step and 64 mg 2-step)
obesitysource ↗
▲Patent GrantedDA-1241IP / Competition
Global patent portfolio for vanoglipel includes 48 granted and pending patents across three families
MASH, diabetessource ↗
◆Oral PresentationPresentation
MetaVia to participate in Life Sciences Virtual Investor Forum fireside chat
▲Patent GrantedDA-1726IP / Competition
Global patent portfolio of 39 granted and pending patents for DA-1726, providing protection into 2041
obesity and related metabolic disorderssource ↗
▲Platform ValidationDA-1241Preclinical
AI-modeling results confirm key therapeutic targets for vanoglipel
MASH, type 2 diabetessource ↗
▼Equity OfferingCorporate
Closing of $9.3 million underwritten public offering with full exercise of allotment option
◆Oral PresentationPresentation
MetaVia to participate in and sponsor 10th Annual MASH-TAG 2026 Conference
▲Topline ReadoutDA-1726Clinical Data
Positive statistically significant results from Phase 1b MAD cohort of DA-1726
obesitysource ↗
Past FDA Catalysts and PDUFA Decisions
How MTVA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-04 | DA-1726 | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 33%
Micro Cap(rank 228 of 689)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA-1726 PeptidesNCT06252220 | Obesity | Phase 1 | RECRUITING | 139 | Nov 9, 2026 | ||||||
| Niclosamide Small MoleculesCompletedNCT04603924 | COVID-19 | Phase 2/3 | COMPLETED | 49 | Feb 16, 2022 | ||||||
| DA-1241 Small MoleculesCompletedNCT06054815 | NON-ALCOHOLIC STEATOHEPATITIS | Phase 2 | COMPLETED | 109 | Oct 30, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every MTVA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| DA-1726 | liver-related diseases | Phase 1 | 2026-11-12 | uric acid reduction: 1.47 mg/dL; liver fat reduction: 68.1%; weight loss: 13.5%; hba1c reduction: 0.44 absolute percentage-pointRead More | MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical TrialRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Woodworth Marshall HOfficer (Chief Financial Officer) | Buy | 14,200 44,279 held | $0.70 | 06/04/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in MTVA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in MTVA for Q2 2026. | ||||
Ownership Trends
MTVA Short Interest
Shares sold short, counted twice a month.
1.18%
Short % of Float
of tradable shares sold short
56.1K
Shares Sold Short
-43.2% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
70.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MTVA ranks across every disease it competes in
Competitive Position is a premium feature
See how MTVA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMTVA News
MTVAMetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update
MetaVia Inc. reported positive interim results for DA-1726 in its Phase 1 Part 3B study, showing a 68.1% reduction in liver fat and 13.5% weight loss. The company plans to initiate a 48-week Phase 2 study for MetALD and ALD in late 2027. Sarah Browne, M.D., has been appointed as Chief Medical Officer to guide further development.
Read more →MTVA▼ -9.7%on this newsshared move
MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial
MetaVia announced positive results from its Phase 1 Part 3B trial of DA-1726, showing a 1.47 mg/dL placebo-adjusted reduction in uric acid after 16 weeks. The treatment also led to a 68.1% reduction in liver fat and 13.5% weight loss. The company plans to advance DA-1726 into a Phase 2 study targeting liver-related diseases in late 2027.
Read more →MTVA▲ +12.6%on this newsshared move
MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek® 2026
MetaVia Inc. announced that its abstract on DA-1726 has been accepted for a poster presentation at ObesityWeek 2026. The presentation will detail DA-1726's comparable weight loss and distinct metabolic profile compared to Retatrutide. The session is scheduled for November 14, 2026, in Washington, DC. DA-1726 is a dual agonist targeting GLP-1 and glucagon receptors.
Read more →MTVA▼ -18.7%on this newsshared move
MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data
MetaVia Inc. announced positive interim results from Part 3B of its Phase 1 trial for DA-1726, showing a 68% reduction in liver fat and a 13.5% weight loss after 16 weeks. The treatment also lowered HbA1c levels significantly. The company plans to advance DA-1726 into a Phase 2 study targeting MetALD and ALD, expected to begin in late 2027.
Read more →MTVAMetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026
MetaVia Inc. announced that an abstract for DA-1726's Phase 1 trial will be presented at the Precision Liver Symposium 2026. The data indicates significant weight loss and improvements in liver health. The presentation will be led by Dr. Sarah Browne on November 4, 2026, in Denver, Colorado.
Read more →MTVAMetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
MetaVia Inc. has appointed Dr. Sarah Browne as Chief Medical Officer, effective October 12, 2026. Dr. Browne brings over 20 years of experience in clinical development, particularly in liver and metabolic diseases. Her expertise will be crucial as MetaVia prepares for upcoming data from its Phase 1 trial of DA-1726 and continues to advance its cardiometabolic pipeline.
Read more →MTVAMetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
MetaVia Inc. announced positive preclinical findings for DA-1726, demonstrating significant tissue distribution and retention in adipose tissue. The study supports the drug's profile as a promising obesity therapy, with previous clinical trials showing a notable reduction in waist circumference. The company anticipates further data from ongoing studies in the coming months.
Read more →MTVAMetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update
MetaVia Inc. reported its second quarter 2026 financial results, highlighting successful dose escalations in its Phase 1 Part 3 study of DA-1726. The company anticipates a significant topline data readout in Q4 2026, showcasing promising results in weight loss and liver health. However, it also reported an increase in net loss and operating expenses compared to the previous year.
Read more →MTVA▲ +10.9%on this news· ran to +24% by day 3
MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
MetaVia Inc. has announced the successful completion of dose titration in Part 3 of its Phase 1 clinical trial for DA-1726, aimed at treating obesity. All active patients have reached their highest target doses, reinforcing the drug's favorable tolerability. The company anticipates reporting topline data in the fourth quarter of 2026, showcasing DA-1726's potential for weight loss and metabolic benefits.
Read more →MTVAMetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
MetaVia Inc. has announced its participation in the upcoming Life Sciences Virtual Investor Forum, where CEO Hyung Heon Kim will present the company's innovative pipeline targeting obesity and metabolic diseases. The forum, set for June 24, 2026, allows real-time interaction between investors and company management. MetaVia is developing two key therapeutic candidates: DA-1726, a dual agonist showing potential for significant weight loss, and vanoglipel, which offers unique benefits for metabolic disorders and liver health. This presentation aims to engage investors and provide insights into their clinical advancements.
Read more →MTVA▼ -13.6%on this news· ran to -26% by day 1
MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
MetaVia Inc. presented new data at the ADA 2026 Scientific Sessions, showcasing promising results for DA-1726, a dual agonist for obesity treatment, which achieved significant weight loss without plateau. Additionally, vanoglipel demonstrated synergistic effects when combined with other therapies in preclinical models for metabolic diseases. The findings support ongoing development and potential combination strategies.
Read more →MTVA▼ -8.6%on this news· ran to -29% by day 3shared move
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
MetaVia Inc. will present its pipeline of innovative obesity and metabolic therapies at the Emerging Growth Conference on June 11, 2026. The company is focused on transforming cardiometabolic diseases with promising candidates such as DA-1726, an oxyntomodulin analogue, and vanoglipel, a GPR119 agonist. Both therapies have shown significant potential in clinical studies for weight loss, glucose control, and liver health. Attendees will have the opportunity to ask questions during and after the presentation.
Read more →MTVA▲ +12.5%on this news
MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
MetaVia Inc. presented promising Phase 1 data for DA-1726 at the EASL Congress 2026, revealing a mean body weight reduction of 9.1% in the 48 mg cohort by Day 54. The compound, a dual GLP-1 and glucagon receptor agonist, demonstrated favorable safety and tolerability, with no serious adverse events reported. Additionally, exploratory assessments indicated early improvements in liver-related parameters, highlighting DA-1726's potential in treating obesity and metabolic dysfunction-associated steatohepatitis (MASH). Ongoing studies aim to evaluate longer-term dosing strategies and optimize treatment durability.
Read more →MTVA▲ +53.7%on this news
MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH
MetaVia Inc. announced a peer-reviewed publication validating the anti-fibrotic potential of vanoglipel, a GPR119 agonist. The study demonstrated that vanoglipel reduced liver fibrosis and supported findings from a Phase 2a clinical trial, where patients showed significant improvements in liver health markers. The publication emphasizes the dual metabolic and anti-fibrotic effects of GPR119 agonism.
Read more →MTVAMetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
MetaVia Inc. announced that three late-breaking abstracts featuring its cardiometabolic assets, DA-1726 and vanoglipel, have been accepted for presentation at the ADA 2026 Scientific Sessions. DA-1726 is currently in a Phase 1 study targeting obesity, while vanoglipel is being explored for its effects on metabolic diseases. The presentations will take place on June 7, 2026, in New Orleans.
Read more →MTVAMetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update
MetaVia Inc. has reported its first-quarter financial results for 2026, highlighting significant progress in its clinical trial for DA-1726, a treatment for obesity. The trial has successfully dosed its first patient under a higher dose regimen, building on previously reported weight loss and glucose control effectiveness. The company anticipates reporting further data by the fourth quarter of 2026 and has noted that the current financial support is essential for this ongoing study. However, MetaVia also faces challenges, including continued net losses and the uncertainty of future clinical trial outcomes.
Read more →MTVAMetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
MetaVia Inc. announced that its dual agonist DA-1726 has been accepted for a late-breaking poster presentation at the EASL Congress 2026. The presentation will focus on DA-1726's safety, tolerability, and pharmacodynamics in treating obesity. The company is currently conducting a Phase 1 study to optimize dosing and assess tolerability, with results expected later this year.
Read more →MTVA▲ +18.5%on this news
MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
MetaVia Inc. has initiated dosing for the first patient in Part 3 of its Phase 1 clinical trial for DA-1726, a dual agonist for obesity treatment. This phase will evaluate two titration strategies over 16 weeks, aiming to optimize dosing and tolerability. Early results indicate significant weight loss and metabolic improvements, with data expected in late 2026.
Read more →MTVAMetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
MetaVia reported $10.3 million in cash at year-end 2025. The company plans to start a Phase 1 study for DA-1726 in April 2026. This trial will test 48 mg and 64 mg dosing regimens. Data from this study is expected in the fourth quarter of 2026.
Read more →MTVAMetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
MetaVia Inc. has received IRB approval for Phase 1 Part 3 trials of DA-1726, a dual agonist targeting GLP-1 and glucagon receptors. The trial will evaluate two dosing strategies over 16 weeks in obese adults. Previous studies indicated significant weight loss and improved metabolic parameters, reinforcing DA-1726's potential as a leading obesity treatment.
Read more →About MetaVia Inc.
Headquarters545 CONCORD AVENUE, CAMBRIDGE, MA, 02138
BIOPHARMAWATCH ELITE
Trade the next MTVA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime